IgA Nephropathy – Landscape & Forecast – Niche & Rare Disease Landscape & Forecast

Immunoglobulin A nephropathy (IgAN), also known as Berger’s disease, is a rare autoimmune disease affecting the kidneys. It is characterized by predominant IgA protein deposition and impairment of blood filtration in the kidneys’ tiny blood channels. Symptoms include high blood pressure, little or no urination, edema, and fatigue. No disease-specific treatments are available; thus, treatment comprises a wide variety of supportive therapies such as antihypertensive drugs, immunosuppressants, and diuretics. High unmet need exists for treatments that can meaningfully delay or halt this progressive end-stage kidney disease. The future of the IgAN therapy market is bright owing to emerging therapies such as sparsentan (Travere Therapeutics), iptacopan (Novartis), narsoplimab (Omeros), and atrasentan (Chinook Therapeutics). Supported by insights from thought leaders, we analyze the challenges associated with marketing drugs to treat an increasingly dynamic and complex disease. Understanding the current and future competitive landscape is critical for marketers of both existing and emerging brands to secure market share or carve out a clinical role.

QUESTIONS ANSWERED

  • What are the sizes of the U.S. and EU5 diagnosed prevalence and incidence IgAN populations? What percentage of the IgAN population receive drug treatment?
  • What are the drivers of and constraints in the IgAN therapy market, and how will the market evolve through 2031?
  • What is the current treatment landscape for IgAN? What are physicians’ experience and satisfaction levels with current key therapies?
  • Which emerging therapies do experts consider most promising? If approved, how will emerging therapies influence the management of IgAN patients? What commercial impact will they have on the IgAN therapy market?

CONTENT HIGHLIGHTS

Geographies: United States and EU5.

Primary research: Six country-specific interviews with thought-leading nephrologists and endocrinologists supported by survey data collected for this study.

Epidemiology: Diagnosed prevalence and incidence cases of IgAN by country, with population-specific drug-treatment rates.

Forecast: Drug-level sales and patient share of key IgAN therapies through 2031.

Emerging therapies: Phase III/preregistered: 5 drugs; Phase II: 7 drugs; coverage of select early-phase products.

PRODUCT DESCRIPTION

Niche & Rare Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Table of contents

  • IgA Nephropathy - Landscape & Forecast - Niche & Rare Disease Landscape & Forecast
    • Key findings
      • IgA Nephropathy Key Findings - May 2022
    • Commercial outlook
      • Key findings
        • Regional sales of key therapies to treat IgA nephropathy: 2031
        • IgA nephropathy SWOT analysis
      • Drivers and constraints
        • What factors are driving sales in IgA nephropathy?
        • What factors are constraining sales in IgA nephropathy?
      • Drug-class-specific trends
        • Renin angiotensin aldosterone system (RAAS) inhibitors
        • Diuretics
        • Immunosuppressants
        • SGLT-2 inhibitors
        • Endothelin receptor antagonists
        • MASP-2 inhibitors
        • Complement factor B inhibitors
        • APRIL inhibitors
    • Forecast
      • Sales of key therapies in IgA nephropathy
    • Etiology and pathophysiology
      • Disease overview
        • Key genetic susceptibility loci in IgA nephropathy
          • Genetic susceptibility loci in IgA nephropathy
        • Key pathways and drug targets
          • Key therapeutic targets
      • Epidemiology
        • Key findings
          • Epidemiology populations
            • Disease definition
            • Methods
            • Sources used for diagnosed prevalence of IgA nephropathy
            • Diagnosed prevalent cases of IgA nephropathy: 2021-2031
            • Diagnosed incident cases of IgA nephropathy: 2021-2031
            • Drug-treated prevalent cases of IgA nephropathy: 2021-2031
        • Current treatment
          • Key findings
            • Treatment goals
              • Key endpoints used in clinical trials for IgA nephropathy
            • Key current therapies
              • Overview
              • Mechanism of Action of Key Current Drug Classes Used for IgA Nephropathy
              • Current treatments used for IgA nephropathy
              • Market events impacting the use of key current therapies in IgA nephropathy
              • RAAS inhibitors
              • Advantages and disadvantages of RAAS inhibitors
              • Expert insight: RAAS inhibitors
              • Diuretics
              • Advantages and disadvantages of diuretics
              • Expert insight: diuretics
              • Corticosteroids
              • Clinical trial outcomes for corticosteroids
              • Advantages and disadvantages of corticosteroids
              • Expert insight: corticosteroids
              • Other immunosuppressive agents
              • Advantages and disadvantages of other immunosuppressants
              • Expert insight: other immunosuppressants
              • Tarpeyo
              • Advantages and disadvantages of Tarpeyo
              • Key results from select clinical trials investigating Tarpeyo for the treatment of IgA nephropathy
              • Analysis of the clinical development program for Tarpeyo (budesonide)
              • Expert insight: Tarpeyo
              • SGLT-2 inhibitors
              • Advantages and disadvantages of SGLT-2 inhibitors
              • Key results from select clinical trials investigating SGLT-2 inhibitors for the treatment of IgA nephropathy
              • Expert insight: SGLT-2 inhibitors
            • Medical practice
              • Overview
              • Factors influencing drug selection in IgA nephropathy
              • Generalized treatment decision tree for IgA nephropathy
          • Unmet need overview
            • Current and future attainment of unmet needs in IgA nephropathy
            • Top unmet needs in IgA nephropathy: current and future attainment
            • Expert insight: unmet need in IgA nephropathy
          • Emerging therapies
            • Key findings
              • Key emerging therapies
                • Key therapies in development for IgA nephropathy
                • Estimated launch dates of key emerging therapies for the treatment of IgA nephropathy
                • Key results from select clinical trials investigating sparsentan for the treatment of IgA nephropathy
                • Key ongoing clinical trials of sparsentan in the treatment of IgA nephropathy
                • Analysis of the clinical development program for sparsentan
                • Expert insight: sparsentan
                • Expectations for launch and sales opportunity of sparsentan in IgA nephropathy
                • Key results from select clinical trials investigating atrasentan for the treatment of IgA nephropathy
                • Key ongoing clinical trials of atrasentan in the treatment of IgA nephropathy
                • Analysis of the clinical development program for atrasentan
                • Expert insight: atrasentan
                • Expectations for launch and sales opportunity of atrasentan in IgA nephropathy
                • Key results from select clinical trials investigating narsoplimab for the treatment of IgA nephropathy
                • Key ongoing clinical trials of narsoplimab in the treatment of IgA nephropathy
                • Analysis of the clinical development program for narsoplimab
                • Expert insight: narsoplimab
                • Expectations for launch and sales opportunity of narsoplimab in IgA nephropathy
                • Key results from select clinical trials investigating iptacopan for the treatment of IgA nephropathy
                • Key ongoing clinical trials of iptacopan in the treatment of IgA nephropathy
                • Analysis of the clinical development program for iptacopan
                • Expert insight: iptacopan
                • Expectations for launch and sales opportunity of iptacopan in IgA nephropathy
                • Key results from select clinical trials investigating sibeprenlimab for the treatment of IgA nephropathy
                • Key ongoing clinical trials of sibeprenlimab in the treatment of IgA nephropathy
                • Analysis of the clinical development program for sibeprenlimab
                • Expectations for launch and sales opportunity of sibeprenlimab in IgA nephropathy
                • Key results from select clinical trials investigating BION-1301 for the treatment of IgA nephropathy
                • Key ongoing clinical trials of BION-1301 in the treatment of IgA nephropathy
                • Analysis of the clinical development program for BION-1301
                • Expectations for launch and sales opportunity of BION-1301 in IgA nephropathy
                • Key results from select clinical trials investigating atacicept for the treatment of IgA nephropathy
                • Key ongoing clinical trials of atacicept in the treatment of IgA nephropathy
                • Analysis of the clinical development program for atacicept
                • Expectations for launch and sales opportunity of atacicept in IgA nephropathy
              • Early-phase pipeline analysis
                • Select compounds in early-phase development (Phase I/II) for IgA nephropathy
              • Patient registries
                • Patient registries for IgA nephropathy
              • Orphan drug designation
              • Access & reimbursement overview
                • Region-specific reimbursement practices
                  • Key Market Access Considerations in IgAN: United States
                  • General reimbursement environment: United States
                  • Key market access considerations in IgA nephropathy: EU5
                  • General reimbursement environment: EU5
              • Appendix
                • IgA nephropathy bibliography

            Login to access report